Kura Oncology, Inc.
KURA
$7.34
$0.050.69%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 53.88M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.88M | -- | -- | -- | -- |
| Cost of Revenue | 155.35M | -- | -- | -- | -- |
| Gross Profit | -101.46M | -- | -- | -- | -- |
| SG&A Expenses | 77.11M | 67.27M | 62.24M | 57.38M | 50.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 247.08M | 217.50M | 200.09M | 183.69M | 165.80M |
| Operating Income | -193.20M | -217.50M | -200.09M | -183.69M | -165.80M |
| Income Before Tax | -171.97M | -197.55M | -181.75M | -168.09M | -152.63M |
| Income Tax Expenses | 2.02M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -173.98 | -197.55 | -181.75 | -168.09 | -152.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.98M | -197.55M | -181.75M | -168.09M | -152.63M |
| EBIT | -193.20M | -217.50M | -200.09M | -183.69M | -165.80M |
| EBITDA | -192.35M | -216.64M | -199.23M | -182.81M | -164.96M |
| EPS Basic | -2.02 | -2.36 | -2.23 | -2.18 | -2.08 |
| Normalized Basic EPS | -1.34 | -1.55 | -1.47 | -1.44 | -1.38 |
| EPS Diluted | -2.02 | -2.36 | -2.23 | -2.18 | -2.08 |
| Normalized Diluted EPS | -1.34 | -1.55 | -1.47 | -1.44 | -1.38 |
| Average Basic Shares Outstanding | 344.63M | 334.83M | 325.12M | 308.28M | 292.78M |
| Average Diluted Shares Outstanding | 344.63M | 334.83M | 325.12M | 308.28M | 292.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
